Is Crinetics Pharmaceuticals, Inc. (CRNX) a Buy, Sell, or Hold?
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$83.71 USD
$0.04 (0.05%)
- Volume
- 5.03M
- Average Volume
- 3.1M
- Market Capitalization
- $8.86B
- P/E Ratio
- -16.29
- Dividend Yield
- 0.00%
- Price Target
- $85.00
- Year High
- $83.89
- Year Low
- $25.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.60
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | R. Scott Struthers |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CRNX |
| CUSIP | 22663K107 |
| CIK | 0001658247 |
| Web | https://www.crinetics.com |
| Phone | 858 450 6464 |
| Currency | USD |
| Employees | 594 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 18.60 |
| Quick Ratio | 18.56 |
| Cash Ratio | 1.61 |
Sales & Book Value
| Annual Sales | $7.7M |
| Price / Sales | 490.34 |
| Cash Flow | -4.03 |
| Price / Cash Flow | -21.12 |
| Price / Book | 6.80 |
Price Target and Rating
| Average Stock Price Forecast | $85.00 |
| High Stock Price Forecast | $85.00 |
| Low Stock Price Forecast | $55.00 |
| Forecast Upside/Downside | -1.52% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 20 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.95 |
| Trailing P/E Ratio | -16.29 |
| PEG Ratio | 0.59 |
| P/E Growth | 0.59 |
| Net Income | $-465.32M |
| Net Margin | -2747.18% |
| Pretax Margin | -2746.18% |
| Return on Equity | -43.96% |
| Return on Assets | -35.42% |
Financials Score
| AltmanZ Score | 42.40 |
| Piotroski Score | 2.00 |
| Working Capital | 1.25B |
| Total Assets | 1.4B |
| Ebit | -496.21M |
| Market Cap | 8.86B |
| Total Liabilities | 120.68M |
Poll Results
About Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another inves ... tigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
2026-07-14 10:31:00
BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
2026-07-14 08:00:00
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
2026-07-13 14:27:07
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
2026-07-11 17:03:07
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.
Why This Pharmaceutical Stock Jumped Close to 100% This Week
2026-07-10 15:02:32
It is getting acquired by a larger firm in the sector.
Why Crinetics Stock Soared 99% This Week
2026-07-09 13:29:39
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
2026-07-09 13:22:00
NEW YORK, July 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) related to its sale to Vertex Pharmaceuticals Incorporated.
2026-07-08 12:33:00
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideratio.
Frequently Asked Questions
-
What is the current Crinetics Pharmaceuticals, Inc. (CRNX) stock price?
-
Crinetics Pharmaceuticals, Inc.(NASDAQ:CRNX) stock price is $83.71 in the last trading session. During the trading session, CRNX stock reached the peak price of $83.885 while $25.83 was the lowest point it dropped to. The percentage change in CRNX stock occurred in the recent session was 0.05% while the dollar amount for the price change in CRNX stock was $0.04.
-
CRNX's industry and sector of operation?
-
The NASDAQ listed CRNX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRNX?
-
Alan S. Krasner | Chief Endocrinologist
Gayathri Diwakar | Head of Investor Relations
Natalie Badillo | Head of Corporate Communications
Tobin C. Schilke | Chief Financial Officer
Kea Lingo | Chief Information Officer -
How many employees does CRNX have?
-
Number of CRNX employees currently stands at 594. CRNX operates from Building No. 2, San Diego, CA 92121, US.
-
Link for CRNX official website?
-
Official Website of CRNX is: https://www.crinetics.com
-
How do I contact CRNX?
-
CRNX could be contacted at phone #858 450 6464 and can also be accessed through its website. CRNX operates from Building No. 2, San Diego, CA 92121, US.
-
How many shares of CRNX are traded daily?
-
The average number of CRNX shares traded daily for last 3 months was 3.1M.
-
What is the market cap of CRNX currently?
-
The market value of CRNX currently stands at $8.86B with its latest stock price at $83.71